NEW YORK, NY, UNITED STATES, April 1, 2026 /EINPresswire.com/ -- Çimsa, a subsidiary of Sabancı Holding and one of the ...
Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission ...
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free ...
(MENAFN- GlobeNewsWire - Nasdaq) Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy ...
The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
STAR-001 is identified for CNS indications by Lantern’s RADR AI platform. Credit: MY STOCKERS / Shutterstock.com. (MY ...
FDA NDA submission for bezuclastinib targets post-imatinib GIST, using Real-Time Oncology Review and supported by prior ...
Designation granted by FDA recognizes the potential of plixorafenib, a novel, investigational paradox breaker and BRAF inhibitor, to provide substantial improvement over available therapies First ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results